Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML ...
Dec 13, 2021
0
1
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by ...
Nov 25, 2021
0
151
More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment ...
Nov 15, 2021
0
10
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in ...
Nov 11, 2021
0
11
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers ...
Nov 9, 2021
0
67
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Then researchers identified safety concerns with the ...
Nov 9, 2021
0
2
A Ludwig Cancer Research study has identified and preclinically validated combination treatments for the brain metastases of breast cancer, a common and typically lethal manifestation of the malignancy. The combination therapy, ...
Oct 18, 2021
0
31
The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line ...
Oct 4, 2021
0
0
The existential threat of COVID-19 has highlighted an acute need to develop working therapeutics against emerging health threats. One of the luxuries deep learning has afforded us is the ability to modify the landscape as ...
Sep 17, 2021
1
81
A Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called "cold" tumors that are nearly devoid of immune cells—and therefore unresponsive to immunotherapy—can ...
Sep 10, 2021
0
15
